Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

Shares of Abbott Laboratories ABT slumped 0.79% to $116.80 Wednesday, on what proved to be an all-around great trading ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. What Is Return On Capital Employed (ROCE)? Just to clarify if you're unsure ...

Shares of Abbott Laboratories ABT rose 4.61% to $118.60 Friday, on what proved to be an all-around positive trading session ...

Juries hit Mead Johnson and Abbott Laboratories with verdicts of $60 million and $495 million respectively earlier this year ...

Following the robust Q3 performance, Piper Sandler raised ABT’s price target to $133 from $131, keeping an Overweight rating ...

In closing arguments on Wednesday, plaintiff's lawyer Timothy Cronin asked jurors for $6 billion in punitive damages.

A jury found Abbott Laboratories and Mead Johnson, owned by U.K.-based Reckitt Benckiser, not responsible for a young boy's intestinal disease, the result of a lawsuit that alleged the companies ...

Nov 1 (Reuters) - Abbott Laboratories (ABT.N), opens new tab shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over ...